NEOCHEM
Neochem Bio Solutions financials
- Market cap
- ₹175 Cr
- Sector
- Chemicals
- Calls analysed
- 1
NEOCHEM Q4 FY26
What went well
- FY26 revenue from operations grew over 32% YoY to INR110.7 crores, driven by broad-based demand.
- EBITDA for FY26 increased 53% YoY to INR22.6 crores, with margins expanding 321 basis points to 20.4% due to favorable product mix and higher capacity utilization.
- PAT for FY26 grew 62% YoY to INR12 crores, with PAT margin improving 197 basis points to 10.6%.
What to watch
- Trade receivables showed a temporary peak, with year-end receivables at INR48 crores, representing 161 days, due to seasonality and clearing MSME payables.
- Geopolitical tensions (West Asia crisis, Russia-Ukraine war) have impacted raw material prices and logistics, with management acknowledging 'some impact would definitely be there' on margins and exports.
What Neochem Bio Solutions Ltd does
Neochem Bio Solutions manufactures specialty performance chemicals across four segments — Polymers, Surfactants, Silicones, and Esters/bio-based sustainable solutions — sold under its own brands to industries including textile and garment washing, home and personal care, institutional and industrial cleaners, water treatment, paints and coatings, paper and pulp, construction, rubber, and dyes and pigments. It runs a single ISO-certified manufacturing facility at Moraiya, Ahmedabad, supported by an in-house R&D lab and QC/QA lab, and sells through a pan-India distributor network as well as exports to select overseas markets.
Segments
- Polymers
- Surfactants
- Silicones
- Esters and bio-based sustainable solutions
- Manufacturing facility
- 1 plant at Moraiya, Ahmedabad (6,763 sq. m)
- Installed capacity
- 22,000 MTPA
- Capacity utilization (FY26)
- 52.7% (11,589 MT produced)
- Customized formulations
- 350+
- Pan-India distributor network
- 50+
- Domestic customers
- 225+
Guidance record · Q4 FY26
what the last two calls moved 8 tracked 0 delivered 0 missed 8 open- Trade Receivables Days open said Q4 FY26 Promised: To bring it to around 120 days, maybe by H1 FY27 or latest by the end of FY27. Q4 FY26: Current level is 161 days.
All 8 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
| Line item | Q4 FY25 | Q4 FY26 |
|---|---|---|
| Revenue | 47 | 65 |
| EBITDA | 8 | 11 |
| Net profit | 6 | 7 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +19.5% YTD
YTD: ₹85.5 on 1 Jan 2026 → ₹102.15. High ₹115.8 (25 May 2026), low ₹63.25 (30 Mar 2026).
How the price took the results
close before → close after
- Q4 FY26
- +14.3%
- 22 May
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Balance sheet
| Year ending | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity capital | ₹3 Cr | ₹5 Cr | ₹7 Cr | ₹7 Cr | ₹17 Cr |
| Reserves | ₹1 Cr | ₹3 Cr | ₹6 Cr | ₹13 Cr | ₹62 Cr |
| Borrowings | ₹23 Cr | ₹26 Cr | ₹33 Cr | ₹36 Cr | ₹18 Cr |
| Other liabilities | ₹19 Cr | ₹16 Cr | ₹18 Cr | ₹24 Cr | ₹20 Cr |
| Total liabilities | ₹46 Cr | ₹51 Cr | ₹63 Cr | ₹79 Cr | ₹117 Cr |
| Fixed assets | ₹12 Cr | ₹15 Cr | ₹19 Cr | ₹19 Cr | ₹20 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹6 Cr |
| Other assets | ₹34 Cr | ₹36 Cr | ₹45 Cr | ₹60 Cr | ₹91 Cr |
| Total assets | ₹46 Cr | ₹51 Cr | ₹63 Cr | ₹79 Cr | ₹117 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Dec 2025, DIIs added +2.63 pp while FIIs trimmed −1.81 pp. The shareholder count shrank 53% to 406.
- Promoters
- 66.7%
- FIIs
- 0.2%
- DIIs
- 15.8%
- Public
- 17.3%
Since Dec 2025
- DIIs +2.63 pp
- FIIs −1.81 pp
- Public −0.84 pp
Who bought this quarter
since Dec 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Swapnil Rameshbhai Makati newly disclosed 54.59% held
- Sanshi Fund-I AIF newly disclosed 2.99% held
- Sheetal Sagar Builders & Developers Private Limited newly disclosed 2.21% held
- Mavira Growth Opportunities Fund AIF +1.89 pp 2.92% held
- Finavenue Capital Trust - Finavenue Growth Fund AIF +1.46 pp 2.66% held
- Aarth AIF Growth Fund AIF newly disclosed 1.37% held
- Venturex Fund I VC / PE +0.49 pp 1.80% held
- Invicta Continuum Fund I AIF +0.06 pp 1.93% held
The same filing shows 1 holder trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Neochem Bio Solutions Ltd above SEBI's 1% disclosure line, and what changed since Dec 2025.
| Holder | Stake | Change |
|---|---|---|
| Swapnil Rameshbhai Makati | 54.59% | newly disclosed |
| Hemangini Swapnil Dathia | 6.31% | unchanged |
| Meenaben Rameshbhai Dathia | 5.82% | unchanged |
| Sanshi Fund-I AIF | 2.99% | newly disclosed |
| Mavira Growth Opportunities Fund AIF | 2.92% | +1.89 pp |
| Finavenue Capital Trust - Finavenue Growth Fund AIF | 2.66% | +1.46 pp |
| Sheetal Sagar Builders & Developers Private Limited | 2.21% | newly disclosed |
| Invicta Continuum Fund I AIF | 1.93% | +0.06 pp |
| Venturex Fund I VC / PE | 1.80% | +0.49 pp |
| Dinesh Chopra | 1.53% | unchanged |
| Aarth AIF Growth Fund AIF | 1.37% | newly disclosed |
| Rikhav Securities Limited Corporate | 1.31% | −0.05 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Neochem Bio Solutions Ltd
Guides on how to read this kind of business and the numbers that matter.